The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Individual patients data analysis (IPD) of three randomized studies comparing erlotinib (E) with chemotherapy (CT) in patients with advanced wild-type epidermal growth factor receptor (wtEGFR) non-small cell lung cancer (NSCLC).
 
Valter Torri
Honoraria - Lilly; Roche/Genentech
Consulting or Advisory Role - Amgen/Dompé
 
Masahiko Ando
No Relationships to Disclose
 
Eliana Rulli
No Relationships to Disclose
 
Irene Claudia Floriani
No Relationships to Disclose
 
Tomoya Kawaguchi
Honoraria - Chugai Pharma; Sanofi
Research Funding - Chugai Pharma
 
Shun-ichi Isa
No Relationships to Disclose
 
Vanesa Gregorc
No Relationships to Disclose
 
Silvia Novello
Honoraria - AstraZeneca; Lilly; MSD; Novartis
 
Sandro Barni
No Relationships to Disclose
 
Michela Cinquini
No Relationships to Disclose
 
Silvia Marsoni
No Relationships to Disclose
 
Gabriella Farina
No Relationships to Disclose
 
Marina Chiara Garassino
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; MSD
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Lilly